Clinical Trials Logo

Brain Neoplasms, Benign clinical trials

View clinical trials related to Brain Neoplasms, Benign.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT06322342 Recruiting - Multiple Sclerosis Clinical Trials

Phase 2 Ascending Dose Safety and Efficacy Study of RVP-001, a Manganese-based MRI Contrast Agent

Start date: March 15, 2024
Phase: Phase 2
Study type: Interventional

This Phase 2 trial will assess the safety, tolerability, efficacy, imaging pharmacodynamics, and pharmacokinetics of RVP-001, a novel manganese-based MRI contrast agent, at three escalating dose levels. RVP-001 will be administered as a single IV bolus to subjects with known gadolinium-enhancing central nervous system (CNS) lesions (for example stable brain tumor or multiple sclerosis) who have recently had a gadolinium-based contrast agent (GBCA)-enhanced MRI of the brain.